In 2019, Zub et al. administered ANXA1 exogenously in an in vivo model of temporal lobe epilepsy and found a decrease in phosphorylated GR (pGR) and pGR/total-GR protein expression in the hippocampus during epileptogenesis, and a continued decrease up to seizure progression and spontaneous recurrent seizure [29]. The gene discussed is NR3C1; the disease is temporal lobe epilepsy.